quantikine ivdtm human epo immunoassay elisa (R&D Systems)
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
95
Structured Review
R&D Systems
quantikine ivdtm human epo immunoassay elisa
Quantikine Ivdtm Human Epo Immunoassay Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 210 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+epo+immunoassay+kit/Human+Erythropoietin+Quantikine+IVD+ELISA+Kit/pmc12612947__jamanetwopen-e2543270-s001-495-8-14
Average 95 stars, based on 210 article reviews
Quantikine Ivdtm Human Epo Immunoassay Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 210 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+epo+immunoassay+kit/Human+Erythropoietin+Quantikine+IVD+ELISA+Kit/pmc12612947__jamanetwopen-e2543270-s001-495-8-14
Average 95 stars, based on 210 article reviews
quantikine ivdtm human epo immunoassay elisa - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Enzyme-linked Immunosorbent Assay:Article Title: Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon ® and Eprex ® following a single subcutaneous administration in healthy male volunteers Article Snippet: .. Quantikine ® IVD ® ELISA, a Article Title: Erythropoietin in amniotic fluid as a potential marker in distinction between growth restricted and constitutionally small fetuses. Article Snippet: Objective: To determine if there is any difference in amniotic fluid erythropoietin (EPO) concentration between fetuses small for gestational age (SGA) and appropriate for gestational age (AGA), and between the constitutionally small (CSF) and growth-restricted (GRF) fetuses.. Methods: EPO concentrations in the amniotic fluid samples were determined by EpoELISA test in 38 pregnancies with SGA and 15 pregnancies with AGA fetuses.. In the SGA group we measured Ponderal index (PI) and skin-fold thickness (SFT). Article Title: Biosimilarity of GBPD002 compared with Eprex ® through clinical evaluation in human Article Snippet: .. Quantikine ® IVD ® ELISA, a Article Title: Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon<sup>®</sup> and Eprex<sup>®</sup> following a single subcutaneous administration in healthy male volunteers Article Snippet: .. Quantikine® IVD® ELISA, a Article Title: Clinical evaluation in adult human revealed the biosimilarity of recombinant Erythropoietin GBPD002 with Eprex® Article Snippet: The biosimilarity for erythropoietin (EPO) functionality of GBPD002 (test candidate) and Eprex® (comparator) has been evaluated by comparing the pharmacokinetic (PK) and pharmacodynamic (PD) properties following subcutaneous injection.. This was a randomized, double-blinded, twosequence, crossover clinical trial.. Subjects were randomly assigned and received a dose (4,000 IU) of either the test or comparator EPO, and received the alternative formulations after 4-weeks of washout period. Article Title: Comparison of the Pharmacokinetic–Pharmacodynamic Relationships of Two Darbepoetin Alfa Formulations in Healthy Male Volunteers Article Snippet: .. Serum darbepoetin alfa concentrations were quantified by a validated enzyme-linked immunosorbent assay (ELISA) method with a Quantikine ® IVD ® ELISA, a Article Title: Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent. Article Snippet: Background and Objectives GC1113, a hybrid Fc-fused erythropoietin, is a novel erythropoiesis-stimulating agent that is expected to have an extended duration of action.. The preclinical data showed that the hemoglobin increase lasted longer following GC1113 administration than it did following the administration of darbepoetin alfa (NESP ).. This study aimed to investigate the pharmacodynamic and pharmacokinetic characteristics and tolerability profiles of GC1113 in humans after single intravenous or subcutaneous administration and to compare the results with those for darbepoetin alfa. Clinical Proteomics:Article Title: "Effects of recombinant human erythropoietin high mimicking abuse doses on oxidative stress processes in rats". Article Snippet: Although many studies highlight how long-term moderate dose of Recombinant Human Erythropoietin (rHuEPO) treatments result in beneficial and antioxidants effects, few studies take into account the effects that short-term high doses of rHuEPO (mimicking abuse conditions) might have on the oxidative stress processes.. Thus, the aim of this study was to investigate the in vivo antioxidant activity of rHuEPO, administered for a short time and at high doses to mimic its sports abuse as doping.. Male Wistar healthy rats (n = 36) were recruited for the study and were treated with three different concentrations of rHuEPO: 7.5, 15, 30 mg/kg. Concentration Assay:Article Title: "Effects of recombinant human erythropoietin high mimicking abuse doses on oxidative stress processes in rats". Article Snippet: Although many studies highlight how long-term moderate dose of Recombinant Human Erythropoietin (rHuEPO) treatments result in beneficial and antioxidants effects, few studies take into account the effects that short-term high doses of rHuEPO (mimicking abuse conditions) might have on the oxidative stress processes.. Thus, the aim of this study was to investigate the in vivo antioxidant activity of rHuEPO, administered for a short time and at high doses to mimic its sports abuse as doping.. Male Wistar healthy rats (n = 36) were recruited for the study and were treated with three different concentrations of rHuEPO: 7.5, 15, 30 mg/kg. Article Title: Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent. Article Snippet: Background and Objectives GC1113, a hybrid Fc-fused erythropoietin, is a novel erythropoiesis-stimulating agent that is expected to have an extended duration of action.. The preclinical data showed that the hemoglobin increase lasted longer following GC1113 administration than it did following the administration of darbepoetin alfa (NESP ).. This study aimed to investigate the pharmacodynamic and pharmacokinetic characteristics and tolerability profiles of GC1113 in humans after single intravenous or subcutaneous administration and to compare the results with those for darbepoetin alfa. |